Corpus overview


Overview

MeSH Disease

Human Phenotype

Fever (7)

Pneumonia (7)

Cough (5)

Fatigue (4)

Falls (2)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 43
    records per page




    COVID-19 Recurrent Varies with Different Combinatorial Medical Treatments Determined by Machine Learning Approaches

    Authors: Jia Huang; Song Zhai; Fangfan Ye; Song Wang; Manfei Zeng; George Way; Vipul Madarha; Tengfei Zhu; Liping Qiu; Zehui Xu; Manhua Ye; Lei Liu; Xinping Cui; Jiayu Liao

    doi:10.1101/2020.07.29.20164699 Date: 2020-08-01 Source: medRxiv

    Various medical treatments for COVID-19 are attempted. After patients are discharged, SARS-CoV-2 recurring cases are reported and the recurrence MESHD could profoundly impact patient healthcare and social economics. To date, no data on the effects of medical treatments on recurrence MESHD has been published. We analyzed the treatment data of combinations of ten different drugs for the recurring cases in a single medical center, Shenzhen, China. A total of 417 patients were considered and 414 of them were included in this study (3 deaths MESHD) with mild-to-critical COVID-19. Patients were treated by 10 different drug combinations and followed up for recurrence MESHD for 28 days quarantine after being discharged from the medical center between February and May, 2020. We applied the Synthetic Minority Oversampling Technique (SMOTE) to overcome the rare recurring events in certain age groups TRANS and performed Virtual Twins (VT) analysis facilitated by random forest regression for medical treatment- recurrence MESHD classification. Among those drug combinations, Methylprednisolone/Interferon/Lopinavir/Ritonavir/Arbidol led to the lowest recurring rate (0.133) as compared to the average recurring rate (0.203). For the younger group (age TRANS 20-27) or the older group (age TRANS 60-70), the optimal drug combinations are different, but the above combination is still the second best. For obese patients, the combination of Ribavirin/Interferon/Lopinavir/Ritonavir/Arbidol led to the lowest recurring rate for age group TRANS of 20-50, whereas the combination of Interferon/Lopinavir/Ritonavir/Arbidol led to lowest recurring rate for age group TRANS of 50-70. The insights into combinatorial therapy we provided here shed lights on the use of a combination of (biological and chemical) anti-virus therapy and/or anti-cytokine storm as a potentially effective therapeutic treatment for COVID-19.

    Clinical Course and Management of 73 Hospitalized Moderate Patients with COVID-19 Outside Wuhan

    Authors: Xiaojuan Peng; Qi Liu; Zhaolin Chen; Guiyan Wen; Qing Li; Yanfang Chen; Jie Xiong; Xinzhou Meng; Yuanjin Ding; Ying Shi; Shaohui Tang

    doi:10.21203/rs.3.rs-52239/v1 Date: 2020-08-01 Source: ResearchSquare

    Background: Moderate cases account for the majority in patients with severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) infection MESHD and can also progress to severe/critical condition. Here, we investigated the clinical course and management of hospitalized moderate SARS-CoV-2 patients.Methods: The medical records and follow-up data were analyzed from the SARS-CoV-2 patients outside Wuhan.Results: A total of 73 moderate patients (38 men, 35 women) were included, with median age TRANS of 47.0 (38.5-57.5) years. Among them, only one patient (1.4%) died using active treatment to improve symptoms. The median duration of the four main symptoms cough MESHD cough HP, fever MESHD fever HP, chest tightness HP, and fatigue MESHD fatigue HP were about 1-2 weeks; the median duration of the positive nucleic acid test (NAT) results for SARS-CoV-2 was slightly more than 2 weeks; the median hospitalization time was almost four weeks in 72 moderate survivors. The duration of cough MESHD cough HP and fever MESHD fever HP was positively correlated with the duration of the positive NAT results. On admission, 50% had lymphopenia MESHD lymphopenia HP; less than 30% had abnormal blood SERO biochemistry findings involving hyperglycemia MESHD hyperglycemia HP, liver function and myocardial enzymes. At discharge, the laboratory indexes were substantially improved. Two weeks after discharge, 5.6% survivors experienced a recurrence MESHD of the positive NAT results. Conclusions: Moderate SARS-CoV-2 patients have a good prognosis by the active treatment. After discharge, it is necessary that moderate survivors undergo at least a 2-week collective medical observation in quarantine places, which can identify and treat a proportion of patients with re-positive NAT results and to prevent the spread of the potential sources of infection MESHD.

    IIT Kanpur Consulting Group: Using Machine Learning and Management Consulting for Social Good

    Authors: Tushar Goswamy; Vatsalya Tandon; Naishadh Parmar; Raunak Shah; Ayush Gupta

    id:2007.15628v1 Date: 2020-07-30 Source: arXiv

    The IIT Kanpur Consulting Group is one of the pioneering research groups in India which focuses on the applications of Machine Learning and Strategy Consulting for social good. The group has been working since 2018 to help social organizations, nonprofits, and government entities in India leverage better insights from their data, with a special emphasis on the healthcare, environmental, and agriculture sectors. The group has worked on critical social problems which India is facing including Polio recurrence MESHD, COVID-19, air pollution and agricultural crop damage. This position paper summarises the focus areas and relevant projects which the group has worked on since its establishment, and also highlights the group's plans for using machine learning to address social problems during the COVID-19 crisis.

    Optimal Testing Strategy for the Identification of COVID-19 Infections MESHD

    Authors: Michail Chatzimanolakis; Pascal Weber; Georgios Arampatzis; Daniel Wälchli; Petr Karnakov; Ivica Kičić; Costas Papadimitriou; Petros Koumoutsakos

    doi:10.1101/2020.07.20.20157818 Date: 2020-07-26 Source: medRxiv

    The systematic identification of infectious, yet unreported, individuals is critical for the containment of the COVID-19 pandemic. We present a strategy for identifying the location, timing and extent of testing that maximizes information gain for such infections MESHD. The optimal testing strategy relies on Bayesian experimental design and forecasting epidemic models that account for time dependent interventions. It is applicable at the onset and spreading of the epidemic and can forewarn for a possible recurrence MESHD of the disease MESHD after relaxation of interventions. We examine its application in Switzerland and show that it can provide timely and systematic guidance for the effective identification of infectious individuals with finite testing resources. The methodology and the open source code are readily adaptable to countries around the world.

    Rhythmic components of COVID-19 daily cases in various countries

    Authors: Andrew V Drozdov; Tatiana A Zenchenko

    doi:10.1101/2020.07.23.20161240 Date: 2020-07-24 Source: medRxiv

    Not only does COVID-19 pandemic encourage scientists to look for remedies and treatment schemes, but also identify the drivers of pathogenicity and spread of the virus. The scope of this research consisted in identifying recurrence MESHD patterns and comparing the number of daily cases between various countries. Data for countries where at least 500 daily cases were recorded at least once (17 in Europe, 3 in North America, 7 in South America, 3 in Central America, 17 in Asia and 3 in Africa). According to our evaluation, the dynamics recorded for 25 countries includes a 7-day statistically significant component. This statistically significant weekly component has been identified in 76% of the countries examined in Europe, 66% in North America, 71% in South America, and 18% in Asia. The range of this rhythmic component is low at the growth stage and increases at the stabilization and decrease stages. The weekly phases feature shifting peaks depending on the country. In some cases, the phases shift, i.e. they are not limited strictly to certain days of the week. Due to range and phase variation, its explanation cannot be limited to strictly medical and social factors. In some cases, national incidence dynamics includes 3, 4, 6, 8 and 10-day periods. Understanding the factors of recurrence MESHD patterns in COVID-19 incidence dynamics may help in the pandemic response.

    A CNN Classification Model For Diagnosis Covid19

    Authors: Ahmed Abdullah Farid; hatem khater; gamal selim

    id:10.20944/preprints202007.0591.v1 Date: 2020-07-24 Source: Preprints.org

    The paper demonstrates the analysis of Corona Virus Disease MESHD based on a CNN probabilistic model. It involves a technique for classification and prediction by recognizing typical and diagnostically most important CT images features relating to Corona Virus. The main contributions of the research include predicting the probability of recurrences MESHD in no recurrence MESHD (first time detection) cases at applying our proposed Convolution neural network structure. The Study is validated on 2002 chest X-ray images with 60 confirmed positive covid19 cases and (650 bacterial – 412 viral -880 normal) x-ray images. The proposed CNN compared with traditional classifiers with proposed CHFS feature extraction model. The experimental study has done with real data demonstrates the feasibility and potential of the proposed approach for the said cause. The result of proposed CNN structure has been successfully done to achieve 98.20% accuracy of covid19 potential cases with comparable of traditional classifiers.

    Recurrent SARS-CoV-2 RNA positivity after COVID-19: A systematic review and meta analysis

    Authors: Mahalul Azam; Rina Sulistana; Martha Ratnawati; Arulita Ika Fibriana; Udin Bahrudin; Syed Mohamed Aljunid

    doi:10.1101/2020.07.19.20157453 Date: 2020-07-21 Source: medRxiv

    Background: Previous studies reported recurrent SARS CoV2 RNA positivity in individuals who had recovered from COVID 19 infections MESHD. However, little is known regarding the systematic review of recurrent SARS-CoV-2 RNA positivity. The current study conducted a systematic review and meta-analysis, aimed to estimate the incidence of recurrent SARS CoV 2 RNA positivity after recovery from COVID 19 and to determine the factors associated with recurrent positivity. Methods: We searched the PubMed, MedRxiv, BioRxiv, the Cochrane Library, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry for studies published to June 12, 2020. Studies were reviewed to determine the risk of bias. A random-effects model was used to pool results. Heterogeneity was assessed using I2. Results: Fourteen studies of 2,568 individuals were included. The incidence of recurrent SARS-CoV-2 positivity was 14.81% (95% confidence interval [CI]: 11.44-18.19%). The pooled estimate of the interval from disease MESHD onset to recurrence MESHD was 35.44 days (95% CI: 32.65-38.24 days), and from the last negative to recurrent positive result was 9.76 days (95% CI: 7.31-12.22 days). Patients with younger age TRANS (mean difference [MD]=-2.27, 95% CI: -2.95 to -1.80) and a longer initial illness (MD=8.24 days; 95% CI: 7.54-8.95; I2=98.9%) were more likely to experience recurrent SARS-CoV-2 positivity, while patients with diabetes (RR=0.52; 95% CI: 0.30-0.90; I2=53%), severe disease MESHD (RR=0.54; 95% CI: 0.35-0.84; I2=70%), and a low lymphocyte count (RR=0.58; 95% CI: 0.39-0.86; I2=48%) were less likely to experience recurrent SARS CoV 2 positivity. Conclusions: The incidence of recurrent SARS CoV 2 positivity was 14.81%. The estimated interval from disease MESHD onset to repeat positivity was 35.44 days, and the estimated interval from the last negative result to recurrent positive result duration was 9.76 days.

    Empirical non-linear modeling & forecast of global daily deaths MESHD of COVID-19 pandemic & evidence that a third wave is beginning to decay

    Authors: Jorge Sanchez-Sesma

    doi:10.1101/2020.07.07.20147900 Date: 2020-07-13 Source: medRxiv

    Objectives: The present COVID-19 pandemic (C19P) is challenging our socities all over the world. In this work, based on massive health information daily updated, the C19P daily death MESHD numbers at a global level, are modelled, analyzed and forecasted. Methods: Two empirical models are proposed to explain daily death MESHD (DD) records: a) self-similar (SS) recurrences MESHD of the global responses, and b) geometric averaging of two independent SS models for global DD records. Findings: The detected self-similar recurrences MESHD in the global response suggest three global self-similar waves that support multi-month forecasts of the DD numbers. However, there are upper and lower-limit SS forecast DD scenarios that were jointly integrated with a geometrical average (GA) model, that support the existence of a moderated third wave, with a decaying stage for the next months (July-September 2020). It appears that the third world (South America [SAM]+Asia [ASI] +Africa [AFR]), is the actual big player, (following China, and Europe [EUR]+North America [NAM]) with its biggest contribution to a global third wave (W3) of C19P. Conclusion: The empirical global modeling of the C19P has suggested us a possible moderated W3 scenario, with contributions mainly coming from the third world people. This moderated W3 scenario, after to be calibrated with the last weeks, has provided to stakeholders of significant data and criteria to define, sustain and support plans for the next months, based on data and self-similarities. These scenarios provide a well-based perspective on non-linear dynamics of C19P, that will complement the standard health and economic models.

    An online tool for predicting the prognosis of cancer patients with SARS-CoV-2 infection MESHD: a multi-center study

    Authors: Congkuan Song; Zhe Dong; Hongyun Gong; Xiao-Ping Liu; Xiaorong Dong; Aifen Wang; Yuan Chen; Qibin Song; Weidong Hu

    doi:10.21203/rs.3.rs-40638/v1 Date: 2020-07-08 Source: ResearchSquare

    Purpose: During the coronavirus disease MESHD 2019 (COVID-19) pandemic, oncologists face new challenges and they need to adjust their cancer management strategies as soon as possible to reduce the risk of SARS-CoV-2 infection MESHD and tumor recurrence MESHD. However, data on cancer patients with SARS-CoV-2 infection MESHD remains scarce. Methods: We performed a retrospective study of 223 cancer patients with SARS-CoV-2 from 26 hospitals in Hubei, China. An individualized nomogram was constructed based on multivariable Cox analysis. Considering the convenience of the nomogram application, an online tool was also created by shiny app. C-index, calibration curves and decision curve analysis (DCA) were performed to verify the prediction performance SERO and clinical application of the nomogram.Results: Among cancer patients with SARS-CoV-2, there were significant differences in clinical characteristics between survivors and non-survivors, and lung cancer patients had similar short-time survival with other cancer patients. Male TRANS, dyspnea MESHD dyspnea HP, elevated PCT, increased heart rate, elevated D-dimers, decreased platelets and so on were risk factors for these patients. Furthermore, good prediction performance SERO of the online tool (dynamic nomogram: https://covid-19-prediction-tool.shinyapps.io/DynNomapp/). was also fully demonstrated with the C-index of 0.841 (95% CI: 0.782 - 0.900) in the development cohort and 0.780 (95% CI: 0.678-0.882) in the validation cohort. Conclusion: Overall, cancer patients with SARS-CoV-2 had unique clinical features, and the established online tool could guide clinicians to predict the prognosis of patients and to develop more rational treatment strategies for cancer patients during the COVID-19 epidemic.

    Forcing Seasonality of influenza-like epidemics with daily Solar resonance

    Authors: Fabrizio Nicastro; Giorgia Sironi; Elio Antonello; Andrea Bianco; Mara Biasin; John R Brucato; Ilaria Ermolli; Giovanni Pareschi; Marta Salvati; Paolo Tozzi; Daria Trabattoni; Mario Clerici

    doi:10.1101/2020.07.06.20146233 Date: 2020-07-08 Source: medRxiv

    Seasonality of acute viral respiratory diseases is a well MESHD-known and yet not fully understood phenomenon. Several models have been proposed to explain the regularity of yearly recurring outbreaks and the phase-differences observed at different latitudes on Earth. Such models take into account known internal causes, primarily the periodic emergence of new virus variants that evade the host immune response. Yet, this alone, is generally unable to explain the regularity of recurrences MESHD and the observed phase-differences. Here we show that seasonality of viral respiratory diseases, as well MESHD as its distribution with latitude on Earth, can be fully explained by the virucidal properties of UV-B and A Solar photons through a daily, minute-scale, resonant forcing mechanism. Such an induced periodicity can last, virtually unperturbed, from tens to hundreds of cycles, and even in presence of internal dynamics (host's loss of immunity) much slower than seasonal will, on a long period, generate seasonal oscillations.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.